Last reviewed · How we verify
NCT06920043
A Phase 2, Randomized, Double-blinded, Placebo-controlled Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Phase 2 trial testing Efimosfermin in Metabolic Dysfunction-Associated Steatohepatitis in 42 participants. Currently enrolling.
1 November 2027
Quick facts
| Lead sponsor | Boston Pharmaceuticals |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 42 |
| Start date | 9 April 2025 |
| Primary completion | 1 November 2027 |
| Estimated completion | 1 December 2027 |
| Sites | 35 locations across United States |
Drugs / interventions tested
- Efimosfermin — full drug profile →
- Placebo
Conditions studied
- Metabolic Dysfunction-Associated Steatohepatitis — all drugs for Metabolic Dysfunction-Associated Steatohepatitis →
Sponsor
Boston Pharmaceuticals — full company profile →
Who can join
Adults 18 to 75, any sex, with Metabolic Dysfunction-Associated Steatohepatitis. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Number of participants with treatment emergent adverse events (TEAEs)
Time frame: From Day 1 to 100 weeks
To assess the effects of efimosfermin on safety and tolerability.
Sponsor's own description
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of efimosfermin in participants with metabolic dysfunction associated steatohepatitis (MASH) and compensated cirrhosis consistent with stage F4 fibrosis.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities.
Prikhodko VA, Okovityi SV. · · 2026 · PMID 42072449 · DOI 10.3390/biomedicines14040909
Verify or expand the search:
- PubMed search for NCT06920043
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Efimosfermin
Trials testing the same drug.
- NCT04880031 — A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an · Phase 2 · completed
Other recruiting trials for Metabolic Dysfunction-Associated Steatohepatitis
Currently open trials in the same condition.
- NCT06939816 — Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) · Phase 2 · recruiting
- NCT06836609 — A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or Wit · Phase 1 · recruiting
- NCT06813508 — Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH · recruiting
Other Boston Pharmaceuticals trials
Trials by the same sponsor.
- NCT04880031 — A Study of BOS-580 in Obese Subjects at Risk for, or With Biopsy-confirmed, Nonalcoholic Steatohepatitis (NASH) With an · Phase 2 · completed
- NCT04221906 — Study to Evaluate the Safety and Antipsoriatic Efficacy of BOS-475 in a Psoriasis Plaque Test · Phase 1 · completed
- NCT04163263 — Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of Repeat Topical Application o · Phase 1 · completed
- NCT04514237 — Study to Determine the Relative Bioavailability, Single and Repeat Dose Pharmacokinetics, Safety and Tolerability of BOS · Phase 1 · completed
- NCT03977155 — Study to Evaluate the Efficacy, Safety, and Tolerability of BOS-589 in the Treatment of Patients With Diarrhea-predomina · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06920043 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Boston Pharmaceuticals
- Last refreshed: 23 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06920043.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing